Journal rankings · indicator year 2005
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Subfield ranking · 2005
Oncology journal rankings 2005
120 ranked journals · Subfield in Medicine
Oncology has 120 ranked journals in 2005. The median journal has an OJR of 0.83, below the world average of 1.00, up 0.03 on 2004; Q1 starts at OJR 1.30. The top three are CA A Cancer Journal for Clinicians, Nature Medicine, and Cancer Cell.
Ranks and citation indicators: 2005. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2002–2004, the window the 2005 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields of Medicine (42)
- Surgery409
- Pulmonary and Respiratory Medicine172
- Public Health, Environmental and Occupational Health145
- Cardiology and Cardiovascular Medicine139
- Oncology120
- Infectious Diseases92
- Epidemiology91
- Psychiatry and Mental health87
- Radiology, Nuclear Medicine and Imaging81
- Neurology76
- Physiology72
- Endocrinology, Diabetes and Metabolism70
Show all 42 subfields
- Orthopedics and Sports Medicine54
- Pediatrics, Perinatology and Child Health52
- Dermatology49
- Hematology48
- Ophthalmology46
- Obstetrics and Gynecology41
- Rheumatology32
- Nephrology31
- Pharmacology31
- Complementary and alternative medicine25
- Reproductive Medicine25
- Emergency Medicine23
- Geriatrics and Gerontology19
- Otorhinolaryngology17
- Pathology and Forensic Medicine17
- Rehabilitation17
- Critical Care and Intensive Care Medicine13
- Immunology and Allergy12
- Hepatology9
- Genetics8
- Anesthesiology and Pain Medicine6
- Gastroenterology6
- Urology6
- Internal Medicine3
- Transplantation2
- Biochemistry1
- Family Practice1
- Anatomy0
- Health Informatics0
- Microbiology0
120 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2004. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2002–2004, the window the 2005 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2002–2004 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2000 to 2005. | Compare |
|---|---|---|---|---|---|---|---|
1CA A Cancer Journal for CliniciansOAWiley · United States | 18.15Q1 | 48.44 5.41 up from 2004 | 63 | 100% | $4,330 | ||
2Nature MedicineNature Portfolio · United States | 5.95Q1 | 14.46no change | 1,207 | 16% | $12,690 | ||
3Cancer CellCell Press · Netherlands | 5.79Q1 | 15.82 0.35 down from 2004 | 427 | 100% | $10,400 | ||
4JNCI Journal of the National Cancer InstituteOxford University Press · United States | 4.45Q1 | 10.32 0.13 up from 2004 | 775 | 29% | $5,436 | ||
5Journal of Clinical OncologyLippincott Williams & Wilkins · United States | 4.24Q1 | 11.02 1.64 up from 2004 | 2,465 | 12% | — | ||
6Clinical Pharmacology & TherapeuticsWiley · United States | 3.33Q1 | 5.89 1.44 up from 2004 | 364 | 3% | $4,410 | ||
7JNCI MonographsOxford University Press · United Kingdom | 3.16Q1 | 6.04 1.46 down from 2004 | 49 | 71% | — | ||
8The Lancet OncologyElsevier BV · United Kingdom | 2.62Q1 | 6.02 0.53 down from 2004 | 347 | 3% | $7,280 | ||
9Seminars in Cancer BiologyElsevier BV · United States | 2.53Q1 | 6.77 0.97 down from 2004 | 190 | 2% | $6,060 | ||
10Clinical Cancer ResearchAmerican Association for Cancer Research · United States | 2.44Q1 | 5.66 5.49 up from 2004 | 1,127 | 33% | — | ||
11CancerWiley · United States | 2.13Q1 | 5.09 0.48 up from 2004 | 2,532 | 60% | $4,790 | ||
12The OncologistOAAlphaMed Press · United Kingdom | 2.03Q1 | 5.34 1.32 up from 2004 | 319 | 65% | $3,852 | ||
13Seminars in OncologyElsevier BV · United States | 1.96Q1 | 4.58 0.41 down from 2004 | 706 | 1% | $3,550 | ||
14Cancer Treatment ReviewsElsevier BV · United Kingdom | 1.93Q1 | 5.30 1.50 up from 2004 | 175 | 3% | $4,910 | ||
15Molecular Cancer TherapeuticsAmerican Association for Cancer Research · United States | 1.91Q1 | 4.60 3.10 up from 2004 | 187 | 35% | — | ||
16British Journal of CancerSpringer Nature · United Kingdom | 1.81Q1 | 4.84 0.90 up from 2004 | 2,130 | 100% | $5,190 | ||
17Journal of Mammary Gland Biology and NeoplasiaSpringer Science+Business Media · United States | 1.79Q1 | 4.16 0.42 up from 2004 | 102 | 12% | $4,090 | ||
18Current Opinion in OncologyLippincott Williams & Wilkins · United Kingdom | 1.74Q1 | 4.11 0.07 up from 2004 | 197 | 1% | — | ||
19Cancer Epidemiology Biomarkers & PreventionAmerican Association for Cancer Research · United States | 1.72Q1 | 4.19 4.09 up from 2004 | 343 | 28% | — | ||
20Cancer Causes & ControlSpringer Science+Business Media · Netherlands | 1.72Q1 | 3.92 0.52 up from 2004 | 349 | 6% | $3,890 | ||
21Critical Reviews in Oncology/HematologyElsevier BV · Netherlands | 1.68Q1 | 3.54 0.37 up from 2004 | 306 | 3% | $4,190 | ||
22Annals of OncologyElsevier BV · Netherlands | 1.67Q1 | 4.09 0.37 up from 2004 | 1,125 | 99% | $5,080 | ||
23International Journal of CancerWiley · United States | 1.66Q1 | 4.55 0.29 up from 2004 | 2,306 | 64% | $5,030 | ||
24Psycho-OncologyWiley · United Kingdom | 1.66Q1 | 2.53 0.09 up from 2004 | 248 | 11% | $4,940 | ||
25European Journal of CancerElsevier BV · United Kingdom | 1.65Q1 | 3.96 0.24 up from 2004 | 1,133 | 11% | $4,270 | ||
26Cancer ControlOASAGE Publishing · United States | 1.56Q1 | 3.45 0.10 down from 2004 | 155 | 44% | $2,650 | ||
27Diseases of the Colon & RectumLippincott Williams & Wilkins · United States | 1.47Q1 | 2.94 0.33 down from 2004 | 831 | 4% | — | ||
28Expert Opinion on Investigational DrugsTaylor & Francis · United Kingdom | 1.43Q1 | 3.61 0.12 down from 2004 | 410 | 2% | — | ||
29JBIC Journal of Biological Inorganic ChemistrySpringer Science+Business Media · Germany | 1.39Q1 | 3.27 0.39 up from 2004 | 284 | 19% | $3,990 | ||
30The Cancer JournalLippincott Williams & Wilkins · United States | 1.30Q1 | 2.79 0.19 up from 2004 | 189 | 0% | — | ||
31BMC CancerOABioMed Central · United Kingdom | 1.22Q2 | 2.53 0.46 down from 2004 | 168 | 100% | $3,390 | ||
32Clinical & Experimental MetastasisSpringer Science+Business Media · Netherlands | 1.20Q2 | 3.44 0.04 down from 2004 | 234 | 7% | $5,090 | ||
33MicrocirculationWiley · United States | 1.16Q2 | 3.19 0.16 down from 2004 | 175 | 6% | $3,920 | ||
34Cancer Immunology ImmunotherapyOASpringer Science+Business Media · Germany | 1.15Q2 | 3.96 0.23 up from 2004 | 376 | 100% | $4,590 | ||
35Surgical OncologyElsevier BV · United Kingdom | 1.14Q2 | 2.83 0.21 up from 2004 | 87 | 0% | $3,890 | ||
36Journal of ImmunotherapyLippincott Williams & Wilkins · United States | 1.13Q2 | 3.61 0.39 down from 2004 | 185 | 3% | — | ||
37Cancer NursingLippincott Williams & Wilkins · United States | 1.12Q2 | 1.53 0.54 down from 2004 | 171 | 2% | — | ||
38Investigational New DrugsSpringer Science+Business Media · Netherlands | 1.09Q2 | 2.74 0.65 up from 2004 | 161 | 6% | $4,690 | ||
39OncologyKarger Publishers · Switzerland | 1.08Q2 | 2.44 0.19 down from 2004 | 418 | 11% | — | ||
40Journal of Cancer Research and Clinical OncologyOASpringer Science+Business Media · Germany | 1.08Q2 | 2.65no change | 323 | 100% | $4,390 | ||
41Journal of Inorganic BiochemistryElsevier BV · United States | 1.05Q2 | 2.49 0.38 up from 2004 | 712 | 7% | $4,220 | ||
42Supportive Care in CancerSpringer Science+Business Media · Germany | 1.02Q2 | 1.90 0.11 up from 2004 | 378 | 9% | $4,690 | ||
43Breast Cancer ResearchOABioMed Central · United Kingdom | 0.99Q2 | 2.81 0.50 up from 2004 | 481 | 100% | $4,190 | ||
44Journal of Clinical PathologyBMJ · United Kingdom | 0.99Q2 | 2.04 0.01 up from 2004 | 904 | 99% | — | ||
45Hematology/Oncology Clinics of North AmericaElsevier BV · United States | 0.98Q2 | 2.21 0.32 up from 2004 | 235 | 0% | $3,950 | ||
46Journal of Medical ScreeningSAGE Publishing · United Kingdom | 0.97Q2 | 2.22 0.11 up from 2004 | 106 | 31% | $4,150 | ||
47Acta OncologicaOATaylor & Francis · United Kingdom | 0.94Q2 | 2.43 0.41 up from 2004 | 281 | 100% | — | ||
48Current Treatment Options in OncologySpringer Science+Business Media · United States | 0.94Q2 | 2.03 0.30 up from 2004 | 147 | 0% | $4,890 | ||
49European Journal of Cancer PreventionLippincott Williams & Wilkins · United States | 0.91Q2 | 2.01 0.12 up from 2004 | 246 | 5% | — | ||
50American Journal of Clinical OncologyLippincott Williams & Wilkins · United States | 0.90Q2 | 1.89 0.01 up from 2004 | 439 | 1% | — |
Subfields of Medicine, with Oncology highlighted.
- Surgery409
- Pulmonary and Respiratory Medicine172
- Public Health, Environmental and Occupational Health145
- Cardiology and Cardiovascular Medicine139
- Oncology120
- Infectious Diseases92
- Epidemiology91
- Psychiatry and Mental health87
- Radiology, Nuclear Medicine and Imaging81
- Neurology76
- Physiology72
- Endocrinology, Diabetes and Metabolism70
- Orthopedics and Sports Medicine54
- Pediatrics, Perinatology and Child Health52
- Dermatology49
- Hematology48
- Ophthalmology46
- Obstetrics and Gynecology41
- Rheumatology32
- Nephrology31
- Pharmacology31
- Complementary and alternative medicine25
- Reproductive Medicine25
- Emergency Medicine23
- Geriatrics and Gerontology19
- Otorhinolaryngology17
- Pathology and Forensic Medicine17
- Rehabilitation17
- Critical Care and Intensive Care Medicine13
- Immunology and Allergy12
- Hepatology9
- Genetics8
- Anesthesiology and Pain Medicine6
- Gastroenterology6
- Urology6
- Internal Medicine3
- Transplantation2
- Biochemistry1
- Family Practice1
- Anatomy0
- Health Informatics0
- Microbiology0
Journals
Citations made in 2005. Corpus-wide, 70.9% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
24 additional Oncology journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2002–2004, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2005. Publication window: 2002–2004. How these summaries are calculated
- Ranked journals
- 120
- Window papers (baseline)
- 53,111 +19.8% from indicator year 2002
- Median OJR
- 0.831 +18.7% from indicator year 2002
- Rising journals (2025)
- 20
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2002–2004 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 82 | 88 | 96 | 103 | 109 | 120 | 120 | 126 | 127 | 134 | 141 | 150 | 153 | 170 | 179 | 188 | 198 | 213 | 224 | 234 | 238 | 239 | 245 | 245 | 243 | 242 | |
| Window papers (baseline) | 37,821 | 41,430 | 44,340 | 47,392 | 49,058 | 53,111 | 57,002 | 62,106 | 66,087 | 71,283 | 77,009 | 82,075 | 86,189 | 88,804 | 93,912 | 98,660 | 102,921 | 105,891 | 109,984 | 115,044 | 121,890 | 139,666 | 156,942 | 167,602 | 163,907 | 160,807 | |
| Median OJR | 0.55 | 0.62 | 0.70 | 0.799 | 0.805 | 0.831 | 0.85 | 0.90 | 0.94 | 0.93 | 1.010 | 0.95 | 1.006 | 0.974 | 0.972 | 0.967 | 0.832 | 0.84 | 0.82 | 0.79 | 0.829 | 0.830 | 0.77 | 0.750 | 0.73 | 0.748 |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.